Chinese regulators have given the green light to Argo Biopharmaceutical to launch a Phase 2 clinical trial testing its treatment…
Articles by Lindsey Shapiro, PhD
Health Canada has approved Roche’s PiaSky (crovalimab) for treating paroxysmal nocturnal hemoglobinuria (PNH) in adults and adolescents, ages…
The U.S. Food and Drug Administration (FDA) has approved Epysqli (eculizumab-aagh), a Soliris (eculizumab) biosimilar, to prevent red blood…
A European Medicines Agency (EMA) committee has recommended the approval of Roche’s PiaSky (crovalimab) to treat people with…
A European Medicines Agency committee has recommended the approval of Voydeya (danicopan) as an add-on treatment for adults with…
The U.S. Food and Drug Administration (FDA) has approved iptacopan for the treatment of adults with paroxysmal nocturnal hemoglobinuria…
Add-on danicopan treatment led to better control of anemia among paroxysmal nocturnal hemoglobinuria (PNH) patients experiencing residual red blood…
Soliris (eculizumab) treatment was associated with a nearly 50% reduction in mortality risk and a 60% lower risk of…
The U.S. Food and Drug Administration (FDA) has cleared for use an injector device intended to make self-administration of…
Long-term treatment with Empaveli (pegcetacoplan) was generally well tolerated among adults with paroxysmal nocturnal hemoglobinuria (PNH), with the rate…